Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 16/20 | 0.47 |
| ▸ | CA12 | O43570 | 6/20 | 0.46 |
| ▸ | CA1 | P00915 | 6/20 | 0.46 |
| ▸ | CA9 | Q16790 | 6/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL4761017 | 0.98 | KMT2A (0.48) | KMT2ACA2CA12CA1CA9 | |
| SCHEMBL4789468 | 0.87 | CA2 (0.46) | KMT2ACA2CA12CA1CA9 | |
| SCHEMBL2606680 | 0.78 | KMT2A (0.52) | KMT2APOLB | |
| SCHEMBL2120202 | 0.76 | KMT2A (0.50) | KMT2APOLB | |
| SCHEMBL31560169 | 0.76 | KMT2A (0.50) | KMT2APOLB | |
| SCHEMBL10402003 | 0.76 | KMT2A (0.50) | KMT2ACA2CA12CA1CA9 | |
| SCHEMBL16732 | 0.76 | KMT2A (0.50) | KMT2APOLB | |
| SCHEMBL5421377 | 0.76 | KMT2A (0.50) | KMT2APOLB | |
| SCHEMBL4802533 | 0.75 | CA2 (0.53) | CA2CA12CA1CA9CA7 | |
| SCHEMBL10534768 | 0.74 | KMT2A (0.48) | KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024115549-A1 | ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-06 | — | — | WO | claimed |
| CN-107021923-B | Tetrahydroquinoline related bicyclic compound and application thereof | 中国科学院广州生物医药与健康研究院 | 2022-09-23 | — | — | CN | claimed |
| CN-114790169-A | Tetrahydroquinoline related bicyclic compound and application thereof | 中国科学院广州生物医药与健康研究院 | 2022-07-26 | — | — | CN | claimed |
| US-4415566-A | ANTIBIOTICS; BACTERIOSTATS; BACTERICIDES | BOEHRINGER INGELHEIM GMBH (DE) | 1983-11-15 | — | — | US | claimed |
| EP-0022494-B1 | BETA-LACTAM-COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC AGENTS CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1983-02-23 | — | — | EP | claimed |
| US-20240400502-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | UNIV QUEENSLAND (AU) | 2024-12-05 | — | — | US | disclosed |
| CN-113582889-B | Sulfonylureas and related compounds and uses thereof | 昆士兰大学 | 2024-09-20 | — | — | CN | disclosed |
| WO-2024115549-A1 | ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-06 | — | — | WO | disclosed |
| US-11845715-B2 | — | — | 2023-12-19 | — | — | US | disclosed |
| WO-2023211990-A1 | BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA V1.8 FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023094830-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | LARIO THERAPEUTICS LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |
| CN-107021923-B | Tetrahydroquinoline related bicyclic compound and application thereof | 中国科学院广州生物医药与健康研究院 | 2022-09-23 | — | — | CN | disclosed |
| EP-1442030-A1 | THIOPENE- AMD THIAZOLESULFONAMIDES AS ANTINEOPLASTIC AGENTS | ELI LILLY AND COMPANY (US) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003035629-A1 | THIOPENE- AMD THIAZOLESULFONAMIDES AS ANTINEOPLASTIC AGENTS | ELI LILLY AND COMPANY (US) | 2003-05-01 | — | — | WO | disclosed |
| US-5302724-A | Thiophenesulfonylureas; anticarcinogenic agents | ELI LILLY AND COMPANY (US) | 1994-04-12 | — | — | US | disclosed |
| CN-1058401-A | Anti-tumor compositions and methods of treatment | LILLY CO ELI (US) | 1992-02-05 | — | — | CN | disclosed |
| EP-0467613-A1 | Antitumor compositions and methods of treatment | ELI LILLY AND COMPANY (US) | 1992-01-22 | — | — | EP | disclosed |
| US-4914206-A | ANTIBIOTICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-04-03 | — | — | US | disclosed |
| EP-0226896-A2 | Lankacidin derivatives and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1987-07-01 | — | — | EP | disclosed |
| US-4415566-A | ANTIBIOTICS; BACTERIOSTATS; BACTERICIDES | BOEHRINGER INGELHEIM GMBH (DE) | 1983-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845715-B2 | — | NLRP3, PYCARD, NOD1 | KMT2A 4317/4885CA2 3818/4885CA12 4772/4885 |
| US-20240400502-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | NLRP3, PYCARD, IAPP | KMT2A 4072/4885CA2 2434/4885CA12 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.